NYSE:CTVA

Corteva Inc. (NYSE: CTVA) Stock Analysis and Price Target

Font: Financial Modeling Prep  • Feb 09, 2026

Market Chart
Corteva Inc. (CTVA) Stock Analysis: Insights and Price Target by UBS

Corteva Inc. (NYSE: CTVA) is a leading figure in the agricultural sector, renowned for its seed and crop protection innovations aimed at enhancing farm productivity and sustainability. On February 9, 2026, UBS analyst Joshua Spector set a price target of $80 for CTVA, indicating a potential upside of 10.19% from its current price of $72.60.

Corteva is navigating through Phase 9 of its 18-phase Adhishthana cycle, a period often linked with bullish breakouts. Despite this, the stock's present configuration signals a need for caution, as per the Adhishthana Principles. Although Phase 9 typically forecasts strength, Corteva's current stance suggests the expected breakout might face hurdles.

The stock's Cakra structure, developed between Phases 4 and 8, is pivotal for predicting its future direction. This formation, resembling a channel with an arc, is designed for a Phase 9 breakout, termed the Himalayan Formation. Corteva embarked on Phase 4 in 2022 and concluded its Cakra by November 2025. Nevertheless, the stock's existing cautionary indicators are significant.

Currently, Corteva's stock is priced at $72.60, marking a modest rise of 0.18% or $0.13. Today, it has fluctuated between $72.16 and $73.87, with a 52-week peak of $77.41 and a trough of $53.40. The company boasts a market capitalization of roughly $49.06 billion, with a trading volume of 3,455,862 shares on the NYSE.

Market Overview
NIVF
NewGenIvf Group Limited
$0.13
27.72%
FNGR
FingerMotion, Inc.
$0.25
41.15%
AMOD
Alpha Modus Holdings, Inc.
$3.49
198.29%
FLUX
Flux Power Holdings, Inc.
$0.64
57.40%
SCNX
Scienture Holdings, Inc.
$0.16
-10.33%
SDEV
NovaBay Pharmaceuticals, Inc.
$7.48
104.37%
NKE
NIKE, Inc.
$33.87
-3.64%
NVDA
NVIDIA Corporation
$233.95
1.34%
QTEX
QTREX Quantum Ltd.
$1.10
40.20%
SPCX
Space Exploration Technologies Corp.
$158.96
7.35%